Published Paper Details:

Diabetes Mellitus (DM) is a prevalent endocrine disorder, affecting 6% of the global population. It is characterized by insufficient insulin production or resistance, leading to elevated blood glucose levels, with serious complications affecting the eyes, kidneys, heart, and nerves. The condition, which dates back to ancient Egypt, is primarily classified into Type 1 and Type 2 diabetes. Type 1 involves the immune system attacking insulin-producing cells, while Type 2 is marked by insulin resistance. Current statistics indicate a rapid increase in Type 2 DM, particularly in developing countries, with projections of 552 million cases by 2030. The development of Floating Drug Delivery Systems (FDDS) represents a significant advancement in oral controlled-release pharmaceuticals, particularly for drugs like Vildagliptin, a DPP-4 inhibitor used to manage Type 2 diabetes. FDDS offers enhanced therapeutic efficacy by ensuring prolonged gastric retention and targeted release in the upper gastrointestinal tract. This system mitigates the fluctuations in drug concentration and improves bioavailability, patient compliance, and clinical outcomes. Vildagliptin, through FDDS, demonstrates improved control over glycemic levels by enhancing insulin secretion and suppressing glucagon release. Floating beads containing Vildagliptin not only maintain stable plasma concentrations but also reduce dosing frequency, leading to better management of diabetes with minimal side effects. The research aims to optimize the formulation of Vildagliptin floating beads to ensure safety, efficacy, and cost-effectiveness in treating Type 2 diabetes